PDCD1 and colorectal carcinoma: In 2015, the KEYNOTE-016 study (NCT01876511) demonstrated that dMMR/MSI-H metastatic CRC (mCRC) patients significantly benefit from programmed cell death protein-1 (PD-1) inhibitors, marking the onset of the immunotherapy era for CRC (6).